NCT03585478View on ClinicalTrials.gov

Latiglutenase as a Treatment for Celiac Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

January 22, 2021

Study Completion Date

January 22, 2021

Conditions
Celiac Disease
Interventions
DRUG

Latiglutenase

Latiglutenase administered orally (daily)

OTHER

Placebo

Placebo administered orally (daily)

Trial Locations (1)

55905

Mayo Clinic - 200 First Street SW, Rochester

Sponsors

Lead Sponsor

Immunogenics, LLC
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

lead

Immunogenics, LLC

INDUSTRY

NCT03585478 - Latiglutenase as a Treatment for Celiac Disease | Biotech Hunter | Biotech Hunter